藥明合聯(02268.HK)2024年擁有人應佔純利10.7億元 同比增長277.2%
格隆匯3月24日丨藥明合聯(02268.HK)公告,截至2024年12月31日止年度,集團取得了驕人的業績。集團收益及毛利呈現強勁增長,分別同比增長90.8%及121.6%至人民幣40.5億元及人民幣12.4億元。此外,公司擁有人應佔純利增長至人民幣10.7億元,同比增長277.2%,而截至2024年12月31日止年度,公司擁有人應佔經調整純利亦增長強勁,增長至人民幣11.74億元,相當於同比增長184.8%。董事會不建議就截至2024年12月31日止年度派付任何末期股息。
基於2023年建立的穩固根基,集團於2024年繼續保持業務快速穩健增長。作爲蓬勃創新的全球生物偶聯藥物行業中的頭部領先企業,集團旨在通過提供世界級的生物偶聯藥物CRDMO服務,並賦權其全球合作夥伴加快及轉變ADC以及更廣泛的生物偶聯藥物開發,以維持其業務快速增長。
集團的CRDMO業務於2023年及2024年呈現強勁勢頭,業務持續積極擴展,全球客戶對其服務的需求亦有所增加。截至2024年12月31日,憑藉其全面的CRDMO能力以及配備從藥物發現到商業化的"一站式"功能的設施,集團已通過提供綜合服務累計賦能全球499名客戶。尤其是集團已成功獲得8個PPQ(工藝驗證)("PPQ")項目及一個商業化階段項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.